Statins in children. Why and when

Area of Science:

• Cardiovascular Medicine
• Pediatric Endocrinology
• Genetics

Background:

• Atherosclerosis originates in childhood, with familial hypercholesterolemia (FH) significantly accelerating its progression.
• Untreated FH (homozygous and heterozygous) leads to substantial morbidity and mortality, with males experiencing earlier and greater risk.
• Current pediatric treatment options like bile acid sequestrants have limitations in efficacy, tolerability, and FDA approval for pediatric use.

Purpose of the Study:

• To review the evidence for atherosclerosis development in childhood, particularly in familial hypercholesterolemia (FH).
• To evaluate the safety and efficacy of lipid-lowering therapies, specifically statins, in pediatric populations with FH.
• To assess the need for re-evaluating current treatment guidelines for pediatric FH.

Main Methods:

• Review of existing literature on childhood atherosclerosis and familial hypercholesterolemia.
• Analysis of studies evaluating lipid-lowering agents, including bile acid sequestrants and statins, in children and adolescents.
• Examination of a large, randomized, placebo-controlled study of lovastatin in adolescent males.

Main Results:

• Familial hypercholesterolemia (FH) significantly accelerates atherosclerosis in children.
• Statins have demonstrated efficacy and acceptable safety in pediatric studies, including a notable trial with lovastatin in adolescent males.
• Existing treatments like bile acid sequestrants have limitations for pediatric use.

Conclusions:

• Statins represent a viable therapeutic option for managing pediatric familial hypercholesterolemia (FH).
• Earlier initiation of therapy, particularly in at-risk males around age 10, is recommended.
• Further well-controlled studies are necessary to confirm clinical benefits and refine treatment guidelines for pediatric FH.